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The diagnosis of chronic kidney disease (CKD) confers dismal
clinical outcomes regardless of whether patients are initiating
dialysis and face a median survival of only 2–3 years or they
have earlier-stage CKD and face a risk of death that is greater
than the risk of progression to dialysis. These poor outcomes
are driven by extraordinarily high rates of cardiovascular
disease that historically have not responded to risk-factor
modification strategies proven to attenuate risk in the
general population. Nor have measures aimed at increasing
the dose or quality of dialysis made an appreciable dent in
mortality. Still worse, interventions that were expected to be
beneficial resulted in increased mortality in recent trials.
Although this apparent lack of progress in advancing the
care of CKD is discouraging, resignation is not an option. On
the contrary, with the rising rates of CKD worldwide, there is
an urgent need to rigorously test novel therapeutic strategies
in randomized trials. The breadth of accumulating evidence
linking disordered phosphorus metabolism to adverse
outcomes spans in vitro, animal, and human studies, and
positions phosphorus management as an attractive target for
intervention. Although opinion-based practice guidelines
promote phosphorus management strategies that are widely
accepted in dialysis patients, there is a clear need to perform
randomized controlled trials to prove or disprove the
benefits of therapy. Perhaps even more important, the
discovery of fibroblast growth factor 23 (FGF23) and its
potential as a novel diagnostic to identify disordered
phosphorus metabolism at an early, subclinical state has
presented the opportunity to develop placebo-controlled
randomized trials in pre-dialysis CKD patients with normal
serum phosphate levels. This commentary considers the
justification and challenges for such trials and presents a
‘first-draft’ blueprint of distinct trial approaches to initiate a
dialog that will ultimately culminate in studies aimed at
improving survival across the spectrum of CKD.
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Chronic kidney disease (CKD) is a growing public health
epidemic that affects B13% of the US population or B26
million people,1,2 and far more worldwide. Although the
overwhelming economic and medical impact of the growing
US dialysis population (stage 5 CKD: 4350,000)3 is widely
recognized, 413,000,000 people in the United States alone
suffer from CKD stages 3 or 4,1,2 which are risk factors for
cardiovascular disease (CVD) mortality.4–7 CVD and CKD
share common risk factors, the presence of CVD is associated
with progressive CKD, de novo and recurrent CVD events are
more common in all stages of CKD, and associated outcomes
are far worse in CKD patients than in the general
population.8–10 As a result of these ‘disease multiplying’
interrelationships, stage 3–4 patients’ risk of death due to
CVD is significantly greater than their risk of progressing to
dialysis.11,12
Given the links between CKD and CVD, considerable
research efforts have focused on strategies to prevent CKD
progression, modify traditional and CKD-specific risk factors
for CVD, and improve survival. Although randomized
studies showed the renoprotective benefits of blocking the
renin–angiotensin system,13–16 attempts to reduce CVD
burden and mortality in CKD have been less successful.17–23
Nevertheless, an accumulating body of exciting clinical and
experimental evidence supports disordered phosphorus
metabolism as a novel target worthy of interventional trials
of renal and cardiac protection in CKD.
ROLE OF PHOSPHORUS EXCESS IN RENAL AND
CARDIOVASCULAR INJURY
Hyperphosphatemia has long been known to exert adverse
effects on bone and parathyroid glands.24–27 During the last
decade, hyperphosphatemia has also emerged as a novel risk
factor for kidney disease progression, vascular calcification,
left ventricular hypertrophy (LVH), and mortality across the
spectrum of CKD.28–31 Prospective studies of non-kidney
disease populations yielded analogous results that provide
strong corroborative evidence in support of the role of
phosphorus in adverse outcomes in CKD.32,33
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Phosphorus and kidney disease progression
Nephrocalcinosis is a pattern of kidney injury related to
phosphorus toxicity,34 and is associated with mitochondrial
disorganization and mineralization of tubular cell mem-
branes,35 factors that may promote tubular cell death and
consequent tubulointerstitial fibrosis.35,36 Experiments in
mildly uremic rats, administered diets with high phosphorus
content,37 showed accelerated kidney disease progression,
and epidemiological studies suggest that higher serum
phosphate levels predict more rapid CKD progression.30,38,39
Moreover, animal and human studies suggest that phos-
phorus-restricted diets may slow the decline in kidney
function.40–42 An important limitation of the human studies,
however, is that more advanced CKD at baseline is the
strongest predictor of progression. Given the relative
imprecision in quantifying renal function, it is possible that
the higher serum phosphates that predicted more rapid
progression actually reflected more advanced CKD at base-
line. Whether the association between increased serum
phosphate levels and renal progression is causal or because of
residual confounding can only be definitively determined by
randomized studies that test whether reducing dietary
phosphorus absorption by decreased intake or by adminis-
tration of phosphorus binders will slow the progression
of CKD.
Phosphorus and vascular injury
Arterial stiffening due to calcification is an independent risk
factor for mortality in the general population and in
CKD.43,44 Severe calcification is more common in CKD than
in people with normal kidney function,45 and has been
associated with mortality on dialysis.46–48 Hyperphosphate-
mia has been linked to arterial calcification in several dialysis
cohorts,45,49–51 in the pre-dialysis population,52 and, more
recently, in patients with preserved kidney function.53 In
support of the epidemiological link between hyperpho-
sphatemia and arterial disease, experimental data indicate
that vascular calcification is an organized cellular process that
begins in early CKD,45,54–58 and is mediated, in part, by
upregulation of osteoblast factors in vascular smooth muscle
cells exposed to high phosphorus concentrations.59–64 Recent
findings of an association between high normal serum
phosphate levels and vascular calcification in pre-dialysis
CKD52 suggest that even lower phosphate concentrations
may contribute to calcification. Further studies are needed to
assess whether interventions targeting phosphorus metabo-
lism in normophosphatemic CKD patients could prevent
progression of vascular disease.
Phosphorus and LVH
Left ventricular hypertrophy is an independent risk factor for
heart failure and mortality in virtually all populations,
including non-CKD,65 pre-dialysis CKD,66 and dialysis.67
Epidemiological studies estimate that the prevalence of LVH
increases progressively with each stage of CKD such that up
to 75% of incident dialysis patients are affected,68 and death
from heart failure accounts for 450% of CVD-related
mortality on dialysis.66 Disordered phosphorus metabolism,
independent of its effects on vascular calcification, is
associated with LVH in CKD,69,70 and animal data support
a direct effect. Rats that underwent parathyroidectomy, 5/6
nephrectomy, and were then administered physiological
replacement doses of parathyroid hormone (PTH) and a
high phosphorus diet developed hyperphosphatemia
and LVH in the absence of vascular calcification71 suggesting
that excess dietary phosphorus resulting in hyperphosphate-
mia may be directly cardiotoxic. In contrast, intensive
daily hemodialysis is an efficient modality for reversing
hyperphosphatemia that was independently associated
with regression of LVH.72–74 Although investigators suggested
a causal link between phosphorus control and regression
of LVH, only randomized trials can offer definitive
confirmation.
Phosphorus and mortality
On the basis of these potential mechanisms of vascular
injury, it is not surprising that large observational studies
have confirmed that hyperphosphatemia is an indepen-
dent risk factor for CVD and mortality on dialysis.28,75,76
These associations were subsequently validated in pre-
dialysis populations29–31 and even in non-kidney disease
populations,32,33 in which subtle increases in serum
phosphate levels within the normal range were linked to
increased risk of death. Although patients with lower
serum phosphate levels were at lower risk of mortality as a
group, whether reducing serum phosphate levels in
individual patients would improve their clinical out-
comes is often assumed, but remains completely un-
studied and unknown.
CURRENT STANDARD OF CARE
The Kidney Disease Outcomes Quality Initiative (NKF/K-
DOQI) Clinical Practice Guidelines for Bone Metabolism
and Disease recommend that serum phosphate levels be
maintained between 2.7 and 4.6 mg per 100 ml in patients
with CKD stages 3 and 4, and between 3.5 and 5.5 mg per
100 ml in dialysis patients.77 Phosphorus reduction strategies,
such as dietary phosphorus restriction or administration of
dietary phosphorus binders, are recommended (although
binders are not FDA (Food and Drug Administration)-
approved in pre-dialysis) when serum phosphate levels
exceed the target range (and secondarily, when PTH levels
exceed its target range). It is critical to emphasize that
these recommendations were published in 2003 by a
working group of experts after meticulous assessment of
the existing literature, which consisted largely of the
aforementioned observational studies that related single
measurements of serum phosphate to survival. The updated
guidelines from the Kidney Disease Improving Global
Outcomes group are expected to also focus on the initiation
of treatment once serum phosphate levels exceed the normal
range.78 Thus, the current standard of care emphasizes the
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management of overt hyperphosphatemia over disordered
phosphorus metabolism in the setting of normal serum
phosphate levels.
LIMITATIONS OF SERUM PHOSPHATE IN THE CLINICAL
MANAGEMENT OF PHOSPHORUS METABOLISM
Although the evidence from large cohort studies linking
hyperphosphatemia with adverse outcomes in pre-dialysis
patients suggests that even subtle increases in serum
phosphate levels within the normal range confer increased
risk,29,32,38 the small absolute differences in serum levels limit
their utility for management decisions in individual patients.
For example, the reported risk estimate for death in one of the
pre-dialysis CKD studies was 23% per 1 mg per 100 ml
increase in serum phosphate levels, yet 50% of patients had
levels within the range of 2.5–3.5 mg per 100 ml.29 By
spanning such a large proportion of patients, relative risk
estimates may sensationalize the actual absolute risk in clinical
practice. Indeed, in a cohort of African-American patients, the
hazard ratio for kidney disease progression was reported to be
1.07 for every 0.3 mg per 100 ml increase in serum phosphate
levels, illustrating a lower absolute risk when a more realistic,
lower per unit change in serum phosphate was used in the
analysis.38 The diurnal and postprandial variability in serum
phosphate levels of up to 1 mg per 100 ml further complicates
the clinical interpretation of risk attributable to smaller
changes in serum phosphate levels.79–81
Furthermore, it is important to note that the widely-
publicized independent association between increased serum
phosphate levels and adverse clinical outcomes comes from
heavily adjusted multivariate models.29,38,53 Indeed, the
results of phosphate and mortality are far less consistent in
the unadjusted analyses reported in these same studies, with
some showing a dampened association with mortality and
others showing a reversed association, whereby higher serum
phosphate levels were protective.53 Significant negative
confounding is clearly a common theme in this area. We
must emphasize that the discrepancies between the un-
adjusted and adjusted analyses do not detract from the
biological importance of phosphorus excess as an indepen-
dent risk factor. Indeed, adjusting for potential confounding
factor is critical to hone in on the true effect of an individual
factor that is interrelated with others. However, the
discrepancy is critical from a clinical perspective, as
nephrologists do not perform multivariate analyses during
clinical encounters. Furthermore, targeting certain serum
phosphate ranges that seem most protective based on
multivariate-adjusted models is fundamentally flawed. As
an example, although a serum phosphate of 7 mg per 100 ml
in a dialysis patient with a concurrent serum albumin of 4.5 g
per 100 ml likely confers significantly less risk than an
identical serum phosphate in a patient with a serum albumin
of 2.5 g per 100 ml, clinical practice guidelines offer no
specific dispensation for these very different situations.
Complicating matters further for the clinician at the point
of care is the fact that the same logic must be carried through
to include upwards of 25 clinical covariates, an impossible
task for clinical decision making. Less confounded biomar-
kers of phosphorus metabolism with greater resolution than
the serum phosphate are desperately needed.
FGF23: AN EMERGING BIOMARKER OF PHOSPHORUS
METABOLISM
Sensitive biomarkers are urgently needed for screening, early
diagnosis, and initiation of therapy for disordered phos-
phorus metabolism before the development of end-organ
damage. Fibroblast growth factor 23 (FGF23) is a key
regulator of phosphorus and vitamin D metabolism that
offers significant promise (Figure 1).82,83 FGF23 is a 251
amino acid protein secreted by osteocytes in adults84 and by
other tissues during development.85 FGF23 binding to FGF
receptor 1c-klotho complex in the kidney86,87 induces
phosphaturia by decreasing phosphate reabsorption in the
proximal tubule88,89 and inhibits renal 25-hydroxyvitamin
D-1-a-hydroxylase leading to decreased conversion of
25-hydroxyvitamin D (25D) to 1,25-dihydroxyvitamin
D (1,25D), the biologically active hormonal form of vitamin
D.90,91 ‘Primary’ syndromes of FGF23 excess, in which FGF23
was originally discovered as the etiological factor, are marked
by hypophosphatemia, renal phosphate wasting, and inap-
propriately low 1,25D levels for the degree of hypopho-
sphatemia. These aspects of FGF23 physiology were
confirmed in transgenic mice that overexpress a cleavage-
resistant FGF23 molecule, in mice administered exogenous
FGF23, and in humans with various syndromes of hypopho-
sphatemia caused by excessive FGF23.92–97 In contrast, FGF23
depletion states, such as FGF23-null mice and patients with
inactivating FGF23 mutations, show hyperphosphatemia
with excessive 1,25D.96,98
The central role of FGF23 in rare disorders of phosphorus
metabolism suggested that it may also regulate phosphorus
and 1,25D homeostasis in health. Through classic negative
endocrine feedback loops, dietary phosphorus intake and
1,25D stimulate FGF23 secretion, which in turn inhibits
1,25D production and increases urinary phosphate excre-
tion.88,99 For example, several days of dietary phosphorus
loading stimulates FGF23 secretion, which induces phospha-
turia and suppresses renal 1,25D.99–101 Phosphorus restriction
exerts the opposite effects: FGF23 levels decrease leading to
renal phosphate reabsorption and enhanced gut absorption
of phosphorus due to increased 1,25D.99–101 Thus, FGF23
seems to help maintain serum phosphate levels within a
narrow range despite fluctuation in dietary phosphorus
intake. Interestingly, it is unknown how the stimuli for
FGF23 secretion are sensed by the secretory cells, and,
perhaps counter-intuitively, changes in serum phosphate
levels do not seem to be the intermediary step, given that
human physiological studies did not observe a change in
FGF23 levels when serum phosphate levels were indepen-
dently altered through a variety of non-dietary strate-
gies.102,103 It is also important to acknowledge that
regulatory mechanisms of urinary phosphate excretion that
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Figure 1 | Fibroblast growth factor 23 (FGF23) regulates serum phosphate levels within a narrow range, despite wide fluctuation in
dietary intake, by a series of classic negative endocrine feedback loops involving 1,25-dihydroxyvitamin D (1,25D), parathyroid
hormone (PTH), urinary phosphate excretion, and dietary phosphorus absorption. FGF23 secretion by osteocytes is primarily
stimulated (þ ) by increased dietary phosphorus intake, exposure to 1,25D, and, possibly, by increased serum phosphate levels; FGF23 is
inhibited () by low dietary phosphorus intake, hypophosphatemia, and low 1,25D levels. FGF23 binds FGF receptor with highest affinity in
the presence of the co-receptor Klotho. In the renal proximal tubule, FGF23 binding increases urinary phosphate excretion by
downregulating expression of luminal sodium–phosphate co-transporters, NaPi-2a and NaPi-2c. In addition, FGF23 inhibits secretion of PTH
and inhibits 25-hydroxyvitamin D-1-a-hydroxylase, leading to decreased circulating levels of 1,25D. Decreased 1,25D levels, in turn, lower
gut phosphorus absorption and release the parathyroid glands from feedback inhibition, thereby increasing circulating PTH levels, which
further augment urinary phosphate excretion. The direct effects of FGF23 on bone mineralization and on other organs are less clear. The
upper insert illustrates the spectrum of FGF23 levels that can be observed under normal conditions and in a variety of syndromes of FGF23
excess. Circulating FGF23 levels are 10- to 20-fold above normal (B30–60 RU/ml using a C-terminal FGF23 assay) in patients with hereditary
hypophosphatemic rickets syndromes, including X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets
(ADHR), autosomal recessive hypophosphatemic rickets (ARHR), and fibrous dysplasia (FD). Although FGF23 levels are often even higher in
patients with tumor-induced osteomalacia (TIO), the highest levels are encountered in patients with kidney disease and especially in those
on dialysis, in whom levels can reach concentrations more than 1000-fold above the normal range. The lower insert illustrates the
differences in the metabolic characteristics of ‘primary’ syndromes of FGF23 excess, such as the hereditary diseases and TIO, versus
‘secondary’ syndromes of FGF23 excess, such as kidney disease. In addition to the severity of the FGF23 increase, the primary difference is
normal to high serum phosphate (Pi) levels in patients with kidney disease compared to those with hypophosphatemia, which is the sine
qua non of the hereditary syndromes. Although variable, 1,25D levels tend to be lower and PTH levels higher in patients with kidney disease
than in those with the hereditary syndromes. Urinary fractional excretion of phosphate is high in both pre-dialysis kidney disease and
genetic hypophosphatemic disorders.
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are independent of FGF23 have been identified in the gut104
and in the central nervous system105 and, based on studies of
primary hypoparathyroidism, FGF23 seems to require at least
some PTH to maintain normal serum phosphate levels.106
Unlike PTH, which changes dynamically in the postprandial
state107 and is affected by concurrent 25D levels,108 FGF23
seems to be relatively stable over time within individual
patients, including those with CKD,107,109 an important
characteristic of a clinically applicable biomarker.
Small studies suggest that FGF23 levels are constitutively
elevated in CKD, presumably as a compensatory response to
maintain normophosphatemia.110–112 Under this hypothesis,
the early and progressive reduction in 1,25D levels in CKD is
less likely due to insufficient renal mass113 and is more likely
due to inhibition by ‘secondary’ FGF23 excess110 in addition
to other factors, such as vitamin D deficiency, down-
regulation of the PTH receptor in the kidney, and accelerated
1,25D degradation.108,114–117 This hypothesis is supported by
cross-sectional studies that showed extremely low rates of
hyperphosphatemia, yet markedly increased FGF23 levels in
pre-dialysis CKD patients, and independent associations
between high FGF23 levels and increased phosphaturia, and
between decreased glomerular filtration rate (GFR) and
1,25D levels.110–112 Moreover, the observation of persistently
low 1,25D levels in the posttransplant period despite
markedly elevated PTH levels and a high prevalence of
hypophosphatemia, each of which should stimulate 1,25D
production by the healthy allograft,118,119 supports an
important role for FGF23 in the early development of
1,25D deficiency in CKD.120,121 Importantly, as increased
FGF23 levels are detectable in early CKD long before
hyperphosphatemia first develops,110 increased FGF23 may
represent an early, more sensitive biomarker of disordered
phosphorus metabolism than concomitant serum phosphate
measurements. A number of recent studies highlight this
potential.
FGF23 AND CLINICAL OUTCOMES
FGF23 and mortality
Given the well-established association between serum
phosphate and mortality,28,29 the relationship between
FGF23 levels and mortality was examined in a prospective,
nested case–control study of 400 incident hemodialysis
patients.122 As hyperphosphatemia is a risk factor for
mortality that correlates with FGF23,110 confounding by
serum phosphate was minimized through frequency match-
ing to randomly select 50 cases and 50 controls within each
quartile of baseline serum phosphate in the overall cohort. As
therapy with activated vitamin D can stimulate FGF23
secretion88,100,101 and has been associated with improved
survival on hemodialysis,76,123–125 patients who initiated
therapy with activated vitamin D before collection of their
baseline blood sample were excluded from the study.
Increased FGF23 levels at the initiation of dialysis were
independently associated with significantly increased risk of
subsequent mortality during the first year on dialysis. The
results were independent of serum phosphate and showed a
strong ‘dose–response’-type relationship such that ascending
quartiles of FGF23 were associated with a linear increase in
risk of mortality (Figure 2a). The highest FGF23 quartile was
associated with a nearly 600% increased risk of death, which
was markedly greater than parallel analyses of phosphate, in
which mortality risk was only 20% greater in the highest
versus the lower quartiles (Figure 2b). Furthermore, in
contrast to the current and previous analyses of serum
phosphate levels and mortality, the association between
















































Figure 2 |Associations between FGF23, phosphate, and
mortality. (a) Crude, case-mix-adjusted, and multivariate-adjusted
odds ratio of mortality according to quartiles of cFGF23 levels
(quartile 1, o1090 RU/ml; quartile 2, 1090–1750 RU/ml; quartile 3,
1751–4010 RU/ml; quartile 4, 44010 RU/ml). The case-mix-
adjusted analysis included the following variables: age, sex, race,
ethnicity, blood pressure, body mass index, standardized mortality
rates, vascular access, history of diabetes, and congestive heart
failure. The multivariate-adjusted analysis included the case-mix
variables plus phosphate, calcium, log PTH, albumin, creatinine,
and ferritin. Quartile 1 is the reference group in all models. Vertical
lines represent 95% confidence intervals. This figure is reproduced
from Gutie´rrez et al,122 with permission from the Massachusetts
Medical Society. (b) Multivariate-adjusted odds ratio of mortality
according to quartiles of serum phosphate (quartile 1, o3.5mg
per 100ml; quartile 2, 3.5–4.4mg per 100ml (reference group, R);
quartile 3, 4.5–5.5mg per 100ml; quartile 4,45.5mg per 100ml);
and quartiles of cFGF23 (quartile 1, o1090 RU/ml (reference
group, R); quartile 2, 1090–1750 RU/ml; quartile 3, 1751–4010
RU/ml; quartile 4, 44010 RU/ml). *Po0.05 compared with the
respective reference group.
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minimal change in the risk estimates comparing the crude
and multivariate-adjusted analyses (Figure 2a). Finally, the
strongest associations between FGF23 and mortality were
observed in the three lower phosphate quartiles (o5.5 mg
per 100 ml), which coincide with the target range of serum
phosphate when therapy is not recommended. The latter
supports a potential role for FGF23 screening as a novel
biomarker to detect which normophosphatemic patients are,
nevertheless, at increased risk of mortality, and thus should
be considered for therapy. In other words, FGF23 could prove
to be a more sensitive and specific marker than the serum
phosphate to guide treatment of disordered phosphorus
metabolism.
At first glance, the increased mortality associated with
high FGF23 levels may seem to be at odds with the survival
benefit attributed to active vitamin D therapy,76,123–125 given
that the latter raises FGF23 levels.88,100,101 However, these
seemingly contradictory findings can be reconciled in a
number of ways. It is possible that the effect of FGF23 excess
on mortality could be modified by treatment with active
vitamin D such that both are independently important, as we
have shown previously for PTH.124 It is also possible that
patients who die early on dialysis despite active vitamin D
therapy might be those with the highest baseline FGF23 levels
or those whose FGF23 levels rose the most in response to
therapy. Finally, it is likely that there is a therapeutic window
for active vitamin D therapy, whereby too high a dose could
be harmful by raising FGF23 excessively, but lower doses
might promote less elevation of FGF23 while garnering the
many proposed benefits of vitamin D.126 Further studies that
include active vitamin D treated and untreated patients are
needed to address these issues.
FGF23 and cardiovascular disease
As CVD is the leading cause of death on dialysis, the
relationship between increased FGF23 levels and mortality
likely involves a cardiovascular mechanism. Three recent
studies support a relationship between FGF23 and vascular
disease and LVH.127–129 In the first study, higher FGF23 levels
were independently associated with impaired vasoreactivity
in 759 patients with normal kidney function and with arterial
stiffness in 208 patients with estimated GFR (eGFR)o60 ml/
min/1.73 m2.127 In the second study of 124 prevalent
hemodialysis patients, higher FGF23, but not serum phos-
phate levels, were independently associated with LVH and
increased left ventricular mass index.128 Most recently,
elevated FGF23 levels were associated with increased left
ventricular mass index and increased prevalence of LVH in
162 pre-dialysis CKD patients, independent of traditional
risk factors and serum phosphate levels, which were not
associated with left ventricular mass index or LVH.129 In
addition, although the highest versus lowest tertile of FGF23
levels was associated with significantly increased risk of severe
coronary artery calcification,129 the statistical significance was
attenuated in multivariate analyses, suggesting a need for
additional studies with greater power. Underlying these
observations, FGF23 could represent a biomarker of total
phosphorus or vascular disease burden,64,122 could exert
direct cardiac and vascular toxicity,64,122 or could act
indirectly by inducing 1,25D deficiency, which is a risk
factor for LVH130 and impaired vascular function in CKD.131
Importantly, although previous studies found serum phos-
phate levels to be associated with vascular stiffness, LVH,
and left ventricular mass index, the results of these studies
again suggest that FGF23 may be superior to serum
phosphate as a marker of the pathophysiological mechanisms
that link disordered phosphorus metabolism with CVD
in CKD.
FGF23 and kidney disease progression
To date, one prospective study of 177 non-diabetic CKD
patients examined the association between FGF23 levels and
kidney disease progression, defined as doubling of serum
creatinine and/or terminal kidney failure.132 During a
median follow-up of 53 months, C-terminal FGF23 levels
4104 RU/ml (or intact FGF23 levels 435 pg/ml) compared
with lower levels were associated with more rapid progression
of CKD independent of age, gender, baseline eGFR,
proteinuria, and serum levels of calcium, phosphate, and
PTH. Although residual confounding by baseline renal
function, and earlier therapy with active vitamin D and
phosphate binders may be potential limitations, if confirmed,
this report suggests that FGF23 may also be a novel marker
for CKD progression. Again, the vast majority of patients
with elevated FGF23 levels had a normal serum phosphate,
highlighting the potential superiority of FGF23 as a marker of
disordered phosphorus metabolism when serum phosphate
levels are normal.
PHOSPHORUS BINDERS AND CLINICAL OUTCOMES
The evidence linking hyperphosphatemia with adverse out-
comes suggests that lowering serum phosphate levels in
individual patients will improve their clinical outcomes.
However, the survival effects of dietary phosphorus restric-
tion and dietary phosphorus binders have not been evaluated
in randomized controlled trials. In fact, all of the phosphorus
binders used in clinical practice were approved by the FDA
on the basis of their efficacy in lowering serum phosphate
levels in short-term studies on dialysis patients rather than in
long-term outcome trials.133–137 Although several trials aimed
to determine which specific phosphorus binder is best for
dialysis patients,138–142 until recently, no studies assessed
whether any phosphorus binder therapy versus none alters
mortality on dialysis.143 In a prospective observational cohort
study of 1-year all-cause mortality in 8610 incident
hemodialysis patients, treatment with phosphorus binders
during the first 90 days of dialysis was independently
associated with an 18–30% lower risk of mortality compared
with no treatment. The results were unchanged in an analysis
that matched treated and untreated patients on their baseline
serum phosphate levels and propensity score of receiving
phosphorus binders. Importantly, the survival benefit was
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independent of serum phosphate levels, suggesting potential
benefits beyond the control of the serum phosphate. Indeed,
recent studies show that phosphorus binders lower FGF23
levels in animals,144 healthy humans,101 dialysis patients,145
and in patients with pre-dialysis CKD.146 Whether aiming to
reduce FGF23 levels using combinations of phosphorus
binders, dietary counseling,147 or salivary phosphate-binding
chewing gum,148 might improve outcomes directly or
whether FGF23 can be used to guide these therapies in
patients with CKD and relatively normal serum phosphate
levels are critical questions with public health implications
that require rigorous testing in randomized trials.
BLUEPRINT FOR RANDOMIZED TRIALS
Dialysis
Given the large body of observational and supportive
experimental data linking phosphorus excess and adverse
outcomes, a clinical trial of phosphorus binders and hard
clinical end points is long overdue for the dialysis population.
However, conducting a placebo-controlled randomized trial
of phosphorus binders on dialysis would likely be viewed as
unethical given the wide acceptance of the current practice
guidelines for maintaining serum phosphate levels between
3.5 and 5.5 mg per 100 ml.77 Although normophosphatemic
dialysis patients could be randomized, many of those in the
placebo arm would soon develop hyperphosphatemia
requiring treatment or withdrawal from the trial, substan-
tially limiting power. Selecting surrogate end points would
shorten the duration of follow-up and thereby prevent
attrition in the placebo arm, but agreeing on an acceptable
surrogate that would obviate the need for hard clinical end
points may not be possible given previous conflicting results
with surrogate markers.138–141
An alternative study design is a randomized controlled
trial to compare the survival of ‘intensive’ versus ‘conven-
tional’ serum phosphate control, for example, comparing a
target serum phosphate level of 4–5 mg per 100 ml with a
target of 6–7 mg per 100 ml. Although the exact target
phosphate levels should be debated, the study design might
mirror diabetes trials targeting different hemoglobin A1C
ranges.149,150 Although some resistance to the possibility of
randomization to a ‘conventional’ arm might be encoun-
tered, we believe clinical equipoise can be justified. First, the
current ‘standard of care’ is largely based on expert
opinion.77 Second, there is no data to suggest that reducing
an individual’s serum phosphate level increases their chance
of survival. Third, it is possible that excessive treatment to
achieve potentially unattainable target phosphate levels in
certain patients might be harmful if it contributed to
excessive calcium loading, osteomalacia, early satiety that
exacerbated malnutrition, or exorbitant cost of medications
and nutritional counseling.77,151,152 Not to be discounted is
the more subtle adverse effect on the dialysis team–patient
relationship resulting from the stigmatization of certain
patients who chronically fail to achieve desired, but perhaps
unnecessary, phosphate targets as ‘non-compliant.’ Finally,
important lessons can be learnt from the diabetes literature,
in which intensive glycemic control was beneficial on a
variety of clinical end points,153,154 but even tighter control to
achieve normalization of hemoglobin A1C was actually
harmful.150
Pre-dialysis CKD
From a public health perspective, the greatest opportunity for
improving the management of phosphorus metabolism in
CKD resides in the millions of stage 3 and 4 patients, 90% of
whom maintain normal serum phosphate levels155 despite
abnormal phosphorus metabolism marked by elevated FGF23
levels.110 Clinical equipoise permits a placebo-controlled
trial, as this population is rarely treated with phosphorus
binders based on current guidelines. Indeed, a recent poll of
practicing nephrologists indicates that onlyB30% of stage 4
CKD patients and less than 20% of stage 3 CKD patients are
treated with phosphorus binders.156 Over 80% of physicians
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Figure 3 |Nephrologists’ attitudes toward phosphorus
management. (a) Serum phosphate levels when nephrologists
(n¼ 303) initiate phosphorus binders in pre-dialysis, chronic
kidney disease patients. (b) Relative willingness of practicing
nephrologists (n¼ 303) to initiate phosphorus binders in patients
with normal serum phosphate levels and pre-dialysis or dialysis-
dependent chronic kidney disease. Data courtesy of the BioTrends
Research Group.156
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before initiating binders, and less than 8% of the surveyed
nephrologists were willing to initiate binder therapy in
normophosphatemic patients (Figures 3a and b).156 The
combination of alarmingly high mortality rates in CKD
stages 3–4,10 clinical equipoise for a placebo-controlled study,
and the emergence of FGF23 as a marker to help identify
which of the millions of normophosphatemic CKD patients
might benefit from FGF23/phosphorus reduction strategies
sets the stage for an innovative randomized trial in
nephrology with implications for the public health.
We propose a placebo-controlled randomized trial of
phosphorus binders in normophosphatemic CKD stage 3B
and 4 (eGFR 15–44 ml/min/1.73 m2) patients.10 Broadly
speaking, eligible patients would have a serum phosphate
o4.6 mg per 100 ml without previous phosphorus binder
therapy, and an FGF23 level above a certain threshold to be
determined. Although hypophosphatemia will likely be an
uncommon event given previous reports of use of phos-
phorus binders in pre-dialysis CKD patients in whom serum
phosphate levels remained in the normal range,157 patients
who develop hypophosphatemia would reduce or discon-
tinue the use of phosphorus binders. A total of 1000 patients
in each arm and a follow-up time of 2 years would provide
90% power with a two-sided alpha of 0.05 to detect a 20%
reduction in mortality in the treatment group, assuming an
incidence density of 10 deaths per 100 person years in the
placebo group, which is equivalent to a median survival of 5
years.10 A smaller sample size could be used if the power is
reduced to 80%, the follow-up duration is extended to allow
more events, or a composite end point including major CVD
events and renal progression is used, as has been done
previously.17,21 Internal data from our group support the
feasibility of identifying a large sample of patients meeting
these inclusion criteria: among normophosphatemic pre-
dialysis CKD patients, 69% of patients with stage 3b and 4
CKD had C-terminal FGF23 levels X100 RU/ml and 46%
had levels X150 RU/ml, which are roughly 2–3 times the
normal range, respectively.
Additional questions will need to be addressed before
embarking on a costly, albeit critically important, rando-
mized, controlled trial. First, it must be shown that the
association between increased FGF23 and mortality observed
among incident dialysis patients is also detectable in the
population to be targeted by the clinical trial, namely patients
in stages 3–4. This could be accomplished in large prospective
cohorts of CKD patients. Second, it must be shown that
treatment with the proposed intervention, specifically phos-
phorus binders, can lead to sustained reductions in FGF23 levels
in the target population. Finally, it will be important to further
develop the plausible biological mechanisms to explain the
potential beneficial effects of reduction of FGF23 and/or dietary
phosphorus absorption, for example, reduction of vascular
stiffness127 or attenuation of LVH.128,129
The outlined objectives will require the mobilization of
the nephrology community and significant resources. As the
findings from the proposed clinical trials, positive or
negative, will certainly affect the management of millions of
patients worldwide, all of the shareholders in the care of
CKD, who will stand to benefit from the results, should
contribute to the support of such a monumental effort. Thus,
financial and logistical support for the trials should come
from a consortium that could include United States
government sources such as NIH and Medicare, correspond-
ing international government agencies, pharmaceutical
companies with interests in CKD, especially those that
manufacture phosphorus binders, large dialysis providers,
and United States and international nephrology societies and
foundations. Although industry sponsorship is essential, their
involvement in the actual design of the specific studies should
be kept at arm’s length to minimize the possibility of real or,
more likely, perceived conflict of interest. Thus, the design of
the study and its management must be led by a multi-
disciplinary team of academic nephrologists, nutritionists,
and other health professionals with specific expertise in
phosphorus metabolism, FGF23, renal nutrition, biostatistics,
and clinical trial conduct.
CONCLUSION
The high prevalence of CKD with its associated CVD risk and
high mortality rates has prompted measures to increase
awareness, promote early diagnosis, and create guidelines for
clinical practice across the spectrum of CKD. The guidelines
for phosphorus management that were driven by the need to
improve the dismal clinical outcomes in CKD are largely
based on expert interpretation of an impressive body of
observational data, but minimal confirmatory randomized
trials. The publication of the guidelines has focused the
nephrology community’s clinical efforts, but equally im-
portantly, they have helped crystallize areas of critical gaps in
our approach. Although it might be tempting to rapidly
advance novel and potentially beneficial therapeutic para-
digms into the clinical setting, especially in such a sick
population as that of CKD, premature adoption of new
‘standards of care’ will further hamper the ability to perform
definitive randomized trials. Nephrologists and regulatory
agencies owe it to their patients to demand these studies. We
propose a first-draft of a blueprint of potential randomized,
controlled trials of different phosphorus management
strategies aimed at improving survival in CKD. Although
the optimal study strategies should be debated, such trials are
urgently needed, a growing body of evidence supports their
feasibility, and the results could dramatically alter the
management of kidney disease patients worldwide.
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